The purpose of Comparative Effectiveness Research is to assist consumers, clinicians, purchasers and policy makers in making informed decisions that will improve healthcare at both the individual and population levels.
The Health Sciences research programme at the UT aims at helping people and their caregivers to communicate and make informed healthcare decisions, and at making sure their voices are heard when the value of healthcare options is being assessed. Our two main application areas are oncology and cardiovascular disease, although our research is not limited to these two areas. The University of Twente has specific expertise in developing methodologies for the evaluation of personalized or precision medicine technologies, such as molecular diagnostics and imaging markers. Our research programme is particularly strong in the evaluation and development of personalized e-Health technologies, healthcare operations research and early Health Technology Assessment (HTA).
Early Health Technology Assessment (HTA), including early Health Economic Modelling, is gaining ground as a means of determining the added value of potential new technologies early in the development pipeline. Early assessment can help the healthcare sector (1) to decide about further development of the technology; (2) to define minimum performance thresholds for the new technology as compared to currently available technologies; and (3) to support pricing and reimbursement in the early stages of development. This discipline includes the investigation of existing regulatory requirements in different countries as well as mechanisms for obtaining reimbursement depending on the added value produced. Early Health Technology Assessment differs from conventional Health Technology Assessment in that it is conducted primarily to inform R&D specialists rather than government (agencies) deciding about coverage.